文献速递精神分裂症与精神病性障碍心境障碍

早期精神病与情感阶段的临床、脑结构与多层级聚类研究

Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

该多中心纵向队列研究对749名发现组和610名验证组的临床高风险精神病、近期起病精神病、近期起病抑郁及健康对照者,采用非负矩阵分解技术分别对临床变量和脑结构体积数据进行聚类,发现临床四维解与所有验证目标相关,脑聚类显示与阴性症状、IQ及精神分裂症多基因风险相关的亚组,结果在外部样本中 largely 验证。

要点

  • 临床四维解基于阳性症状、阴性症状、抑郁和功能分离个体,与所有验证目标相关。
  • 脑聚类揭示一个脑体积减少亚组,与阴性症状、操作IQ降低及精神分裂症多基因风险评分升高相关。
  • 多层级结果区分了正常变异与疾病相关脑差异,亚组结果在外部样本中 largely 验证。

核心结论

  • 纵向队列研究结果提供了超越阳性症状表达的分层,横跨疾病阶段和诊断。
  • 临床结果提示阴性症状、抑郁和功能的重要性。
  • 脑结果提示疾病阶段间及正常变异间存在大量重叠,可能突出独立于特定表现的脆弱性特征。
  • 病前、纵向和遗传风险验证提示亚组对预防性治疗具有临床重要性。

研究设计与样本

  • 多中心、自然主义、纵向队列研究,涉及5个欧洲国家的10个站点,主要随访间隔为9个月和18个月。
  • 发现组749人,验证组610人,包括临床高风险精神病(CHR-P)n=287、近期起病精神病(ROP)n=323、近期起病抑郁(ROD)n=285和健康对照n=464。
  • 平均(SD)年龄25.1(5.9)岁,女性702人(51.7%)。
  • 采用非负矩阵分解技术分别分解临床(287个变量)和脑结构体积(204个灰质、白质和脑脊液区域)数据,使用嵌套交叉验证确定聚类数。
  • 验证目标包括病前、纵向和精神分裂症多基因风险评分,多类监督机器学习生成可转移解决方案至验证样本。

主要发现

  • 临床四维解基于阳性症状、阴性症状、抑郁和功能分离个体,与所有验证目标相关。
  • 脑聚类揭示一个亚组,其分布性脑体积减少与阴性症状、操作IQ降低及精神分裂症多基因风险评分升高相关。
  • 多层级结果区分了正常变异与疾病相关脑差异。
  • 亚组结果在外部样本中 largely 验证。

关键数值与推荐

  • 临床聚类使用287个变量,脑结构聚类使用204个区域。
  • 发现组749人,验证组610人。
  • 平均年龄25.1(SD 5.9)岁,女性占51.7%。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Approaches are needed to stratify individuals in early psychosis stages beyond positive symptom severity to investigate specificity related to affective and normative variation and to validate solutions with premorbid, longitudinal, and genetic risk measures. OBJECTIVE: To use machine learning techniques to cluster, compare, and combine subgroup solutions using clinical and brain structural imaging data from early psychosis and depression stages. DESIGN, SETTING, AND PARTICIPANTS: A multisite, naturalistic, longitudinal cohort study (10 sites in 5 European countries; including major follow-up intervals at 9 and 18 months) with a referred patient sample of those with clinical high risk for psychosis (CHR-P), recent-onset psychosis (ROP), recent-onset depression (ROD), and healthy controls were recruited between February 1, 2014, to July 1, 2019. Data were analyzed between January 2020 and January 2022. MAIN OUTCOMES AND MEASURES: A nonnegative matrix factorization technique separately decomposed clinical (287 variables) and parcellated brain structural volume (204 gray, white, and cerebrospinal fluid regions) data across CHR-P, ROP, ROD, and healthy controls study groups. Stability criteria determined cluster number using nested cross-validation. Validation targets were compared across subgroup solutions (premorbid, longitudinal, and schizophrenia polygenic risk scores). Multiclass supervised machine learning produced a transferable solution to the validation sample. RESULTS: There were a total of 749 individuals in the discovery group and 610 individuals in the validation group. Individuals included those with CHR-P (n = 287), ROP (n = 323), ROD (n = 285), and healthy controls (n = 464), The mean (SD) age was 25.1 (5.9) years, and 702 (51.7%) were female. A clinical 4-dimensional solution separated individuals based on positive symptoms, negative symptoms, depression, and functioning, demonstrating associations with all validation targets. Brain clustering revealed a subgroup with distributed brain volume reductions associated with negative symptoms, reduced performance IQ, and increased schizophrenia polygenic risk scores. Multilevel results distinguished between normative and illness-related brain differences. Subgroup results were largely validated in the external sample. CONCLUSIONS AND RELEVANCE: The results of this longitudinal cohort study provide stratifications beyond the expression of positive symptoms that cut across illness stages and diagnoses. Clinical results suggest the importance of negative symptoms, depression, and functioning. Brain results suggest substantial overlap across illness stages and normative variation, which may highlight a vulnerability signature independent from specific presentations. Premorbid, longitudinal, and genetic risk validation suggested clinical importance of the subgroups to preventive treatments.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Dwyer DB, Buciuman MO, Ruef A, et al. Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages. JAMA Psychiatry. 2022. PMID: 35583903. doi:10.1001/jamapsychiatry.2022.1163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。